S Biomedics Co., Ltd. (304360)
KRX SM KRX SM Primary Summary
S Biomedics Co., Ltd. (304360) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has S Biomedics Co., Ltd. ever had a stock split?
S Biomedics Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | KRX SM Exchange | - ISIN |
| South Korea Country | 54 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
S.Biomedics CO., LTD., established in 2005 and headquartered in Seoul, South Korea, is a pioneering biopharmaceutical company dedicated to progressing the field of stem cell therapy. With a strong commitment to innovation, the company focuses on the discovery, development, and delivery of novel stem cell therapies for various medical conditions. Through rigorous research and development, S.Biomedics CO., LTD. has emerged as a significant player in the biopharmaceutical industry, leveraging its expertise in stem cell technology to address unmet medical needs and enhance patient outcomes.
Products and Services
- TED-N
- TED-A9
- FECS-Ad
- FECS-DF
- TED-R
- CF-TED-N
- CF-FECS-DF
Currently in phase 1/2a clinical development, TED-N represents a groundbreaking stem cell therapy product aimed at treating subacute spinal cord injuries. This product embodies the company's dedication to revolutionizing the field of regenerative medicine and providing new hopes for patients with spinal cord injuries.
At the forefront of its phase 1/2a clinical development, TED-A9 is being developed for the treatment of Parkinson's disease. This innovative therapy highlights S.Biomedics' commitment to addressing neurodegenerative disorders and improving the quality of life for patients suffering from Parkinson's disease.
In phase 1/2a clinical trials, FECS-Ad is a novel therapy aimed at treating critical limb ischemia. By utilizing advanced stem cell technologies, this product seeks to provide a solution for patients facing potential amputation due to severe blockages in the arteries of their limbs.
Undergoing phase 1/2 clinical development, FECS-DF targets the treatment of crow's feet, offering a regenerative approach to cosmetic issues. This therapy exemplifies the company's efforts to extend stem cell applications beyond life-threatening conditions to improve overall well-being and cosmetic appearance.
Designed for the treatment of macular degeneration, TED-R is part of S.Biomedics' expansive pipeline aimed at combating major causes of vision loss. This therapy underscores the company's dedication to addressing a wide range of medical conditions through innovative stem cell therapies.
CF-TED-N is being developed for the treatment of stroke, reflecting S.Biomedics' commitment to extending the therapeutic potential of stem cells to neurovascular disorders. This therapy represents an important step towards offering novel treatment options for stroke recovery.
Targeting the treatment of wounds, CF-FECS-DF leverages stem cell therapy to enhance the healing process. This product is indicative of the company's broader efforts to harness stem cell technology for regenerative purposes, aiding in the recovery of various types of wounds.
In addition to its impressive product pipeline, S.Biomedics CO., LTD. offers comprehensive testing services and possesses proprietary platform technologies that underpin its cell therapy products. Through these services and technologies, the company is well-equipped to lead advancements in the field of stem cell therapy and deliver innovative solutions that meet the complex needs of patients globally.
